Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. Issue 8 (14th February 2018)

• Record Type: Journal Article
• Authors: Barrera, José; Schutta, Christopher; Pisano, Melia; Grubman, Marvin J.; Brake, David A.; Miller, Timothy; Kamicker, Barbara J.; Olutunmbi, Femi; Ettyreddy, Damodar; Brough, Douglas E.; Butman, Bryan T.; Neilan, John G.
• Is Part Of: Vaccine. Volume 36:Issue 8(2018)
• Page Start: 1078
• Page End: 1084
• Publication Date: 2018-02-14
• Subjects: AdtA24 replication-deficient human adenovirus vectored FMDV A24/Cruzeiro/BRA/55 vaccine -- APHIS Animal and Plant Health Inspection Services -- CVB Center for Veterinary Biologics -- DIVA differentiate infected from vaccinated animals -- dpc days post-challenge -- dpv days post-vaccination -- FFB final formulation buffer -- FMD foot-and-mouth disease -- FMDV foot-and-mouth disease virus -- GMT geometric mean VNT titer -- NSP nonstructural protein -- PU particle units -- USDA United States Department of Agriculture -- VNT virus neutralization test; Foot-and-mouth disease virus -- FMDV A24/Cruzeiro/BRA/55 -- Recombinant human adenovirus vectored vaccine -- DIVA -- Vaccine efficacy -- Adjuvant; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.01.026
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: One dose of AdtA24 + adjuvant prevented clinical FMD at 7 and 14 dpv. AdtA24 + adjuvant improved protection for FMD and viremia vs. a 4× AdtA24 dose alone. AdtA24 + adjuvant enhanced the FMDV neutralization titer vs. a 4× AdtA24 dose alone. AdtA24 + adjuvant dosed 7 or 14 days before FMDV exposure reduced nasal virus shedding. Abstract: A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.